autosomal dominant alzheimer disease: a unique resource to study csf biomarker changes in preclinical ad
Clicks: 212
ID: 187576
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
212 views
34 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #219 of 263 articles by views in journal of photochemistry and photobiology a: chemistry
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 263 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Our understanding of the pathogenesis of Alzheimer disease (AD) has been greatly influenced by investigation of rare families with autosomal dominant mutations that cause early onset AD. Mutations in the genes coding for Amyloid Precursor Protein (APP), Presenilin 1 (PSEN-1) and Presenilin 2 (PSEN-2) cause over-production of the amyloid-beta peptide (Abeta) leading to early deposition of Abeta in the brain, which in turn is hypothesized to initiate a cascade of processes resulting in neuronal death, cognitive decline and eventual dementia. Studies of cerebrospinal fluid (CSF) from individuals with the more common late-onset form of AD (LOAD) has revealed that low CSF Abeta42 and high CSF tau are associated with AD brain pathology. Herein we review the literature on CSF biomarkers in autosomal dominant AD (ADAD) which has contributed to a detailed road map of AD pathogenesis, especially during the preclinical period, prior to the appearance of any cognitive symptoms. Current drug trials are also taking advantage of the unique characteristics of ADAD and utilizing CSF biomarkers to accelerate development of effective therapies for AD.
| Reference Key |
schindler2015frontiersautosomal
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Suzanne Elizabeth Schindler;Anne M Fagan |
| Journal | journal of photochemistry and photobiology a: chemistry |
| Year | 2015 |
| DOI |
10.3389/fneur.2015.00142
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.